T2 Biosystems to Commercialize Test for Early Lyme Disease
T2 Biosystems plans to commercialize, a diagnostic test for early Lyme disease, with a goal of releasing it in the U.S. as an LDT in 2023.
Read MorePosted by Chris Wolski | Oct 14, 2022 | Allergy & Autoimmune |
T2 Biosystems plans to commercialize, a diagnostic test for early Lyme disease, with a goal of releasing it in the U.S. as an LDT in 2023.
Read MorePosted by Chris Wolski | Oct 13, 2022 | Gastrointestinal Infections |
Researchers have created a method that makes sewage monitoring possible for a virus that may be linked to hepatitis outbreaks worldwide.
Read MorePosted by Chris Wolski | Oct 10, 2022 | Prenatal Testing |
Diagnostic screening for Down’s Syndrome during pregnancy was difficult until the development of an NIPT fetal fraction test.
Read MorePosted by Bryce Lochmann | Oct 10, 2022 | Disease States |
Multiplex testing offers labs a way to conclusively efficiently, and cost effectively diagnose patients presenting with symptoms that could be COVID or flu, cutting time to diagnosis and improving time to treatment.
Read MorePosted by Andy Lundin | Oct 7, 2022 | Immunoassay |
Siemens Healthineers’ INNOVANCE VWF Ac fully-automated assay for Von Willebrand disease is now available to U.S. laboratories.
Read More